EGFR and lung adenocarcinoma: Furthermore, in an analysis of 860 patients with lung adenocarcinoma who were prospectively tested for actionable mutations, one patient (100%) with an EGFR L833V mutation in conjunction with an EGFR L858R substitution mutation who received EGFR TKI therapy and chemotherapy had clinical benefit [10].